CD36 and ovarian cancer: In addition to the methods described above, Jayawardhana et al. designed a Pt(iv) prodrug that mimics the structure of a fatty acid, entering ovarian cancer cells via CD36 and triggering mitochondrial damage, thereby eliminating ovarian cancer cells [154].